Since DOX has been the backbone of current standard combination chemotherapy regimens for treating breast cancer, we propose that increased PKR in primary breast cancer vs. normal tissue may represent a positive prognostic biomarker for response to chemotherapy and contribute to DOX’s favorable therapeutic index when used to treat breast cancer. Here, EIF2AK2 is linked to breast cancer.